Induced Pluripotent Stem Cell-Derived Endothelial Cells Overexpressing Interleukin-8 Receptors A/B and/or C-C Chemokine Receptors 2/5 Inhibit Vascular Injury Response

SAMANTHA GIORDANO, a,b*, XIANGMIN ZHAO, a,b*, YIU-FAI CHEN, a,b SILVIO H. LITOVSKY, b FADI G. HAGE, a,c TIM M. TOWNES, d CHIAO-WANG SUN, d LI-CHEN WU, d SUZANNE OPARIL, d DONGQI XING a

Key Words. iPSC-endothelial cells • Targeted cell therapy • Vascular injury • Interleukin 8 receptor • C-C chemokine receptor 2/5

ABSTRACT

Recruitment of neutrophils and monocytes/macrophages to the site of vascular injury is mediated by binding of chemoattracants to interleukin (IL) 8 receptors RA and RB (IL8RA/B) C-C chemokine receptors (CCR) 2 and 5 expressed on neutrophil and monocyte/macrophage membranes. Endothelial cells (ECs) derived from rat-induced pluripotent stem cells (RiPS) were transduced with adenovirus containing cDNA of IL8RA/B and/or CCR2/5. We hypothesized that RiPS-ECs overexpressing IL8RA/B (RiPS-IL8RA/B-ECs), CCR2/5 (RiPS-CCR2/5-ECs), or both receptors (RiPS-IL8RA/B+CCR2/5-ECs) will inhibit inflammatory responses and neointima formation in balloon-injured rat carotid artery. Twelve-week-old male Sprague-Dawley rats underwent balloon injury of the right carotid artery and intravenous infusion of (a) saline vehicle, (b) control RiPS-Null-ECs (ECs transduced with empty virus), (c) RiPS-IL8RA/B-ECs, (d) RiPS-CCR2/5-ECs, or (e) RiPS-IL8RA/B+CCR2/5-ECs. Inflammatory mediator expression and leukocyte infiltration were measured in injured and uninjured arteries at 24 hours postinjury by enzyme-linked immunosorbent assay (ELISA) and immunohistochemistry, respectively. Neointima formation was assessed at 14 days postinjury. RiPS-ECs expressing the IL8RA/B or CCR2/5 homing device targeted the injured arteries and decreased injury-induced inflammatory cytokine expression, neutrophil/macrophage infiltration, and neointima formation. Transfused RiPS-ECs overexpressing IL8RA/B and/or CCR2/5 prevented inflammatory responses and neointima formation after vascular injury. Targeted delivery of iPSC-ECs with a homing device to inflammatory mediators in injured arteries provides a novel strategy for the treatment of cardiovascular diseases. STEM CELLS TRANSLATIONAL MEDICINE 2017;6:1168–1177

SIGNIFICANCE STATEMENT

One major unsolved problem for cell-based therapy is how to home transplanted cells to damaged organs to improve their survival and to enhance tissue repair and organ function. When equipped with certain chemokine receptors as a homing device, induced pluripotent stem cell-derived endothelial cells mimic the behavior of neutrophils/macrophages and compete with the binding of these cells to chemokines overexpressed in injured tissue, thus inhibiting inflammatory response and adverse vascular remodeling following vascular injury. The results of the present study open the door to new therapeutic applications of cell therapy in patients with cardiovascular injury.

INTRODUCTION

Vascular inflammation that results from endothelial injury is a major contributor to most forms of cardiovascular disease (CVD). We have shown that the response to acute endoluminal vascular injury occurs in two phases [1–7]. The first phase, which begins immediately after injury and lasts for ~48 hours, is characterized by increased inflammatory cytokine production and leukocyte (neutrophil, monocyte/macrophage, and T-cell) infiltration into the injured vasculature [1, 4, 8–10]. Previous work in the rat carotid artery balloon injury model demonstrated a significant increase in expression of cytokine-induced neutrophil chemoattractant (CINC)—2β (human homolog of IL8) and C-C chemokine ligand 2 (CCL2)/monocyte chemoattractant protein-1 (MCP-1) in injured arteries within 24 hours postinjury [1, 4, 8–10]. The second phase, which lasts for ~4 weeks in rodents, is characterized by an increase in fibroblast and...
smooth muscle cell proliferation, myofibroblast transformation, and migration toward the lumen to form the neointima [3, 5–7, 10, 11].

Neutrophils expressing IL8 and B receptors are among the first wave responders that infiltrate injured tissues in response to locally expressed IL8 and exacerbate the inflammatory response by upregulating other inflammatory cytokines (e.g., CCL2/MCP-1), causing influx of second wave responders, including monocytes/macrophages. We have shown that targeted cell therapy with adult rat aortic endothelial cells (RAECs) transfected with IL8 receptors A and B (IL8RA/B-ECs) attenuates inflammation and neo-intima formation in balloon injured rat carotid arteries [10, 12].

Monocytes/macrophages express C-C chemokine receptor type 2 (CCR2) and 5 (CCR5) receptors and migrate toward the monocyte/macrophage chemotactic including CCL2/MCP-1 that is expressed in injured tissues [13, 14]. We have shown that CCL2/MCP-1 mRNA and protein expression are increased in rat carotid arteries 24 hours after balloon injury and that monocytes/macrophages infiltrate injured arteries with 24 hours after vascular injury [1, 4, 10, 12, 15]. Both neutrophils and monocytes/macrophages may contribute to inflammation-stimulated neo-intima formation in injured arteries. In the current study, we used endothelial cells (ECs) overexpressing IL8RA/R8, CCR2/5, or both types of receptors as targeted cell therapy to define the roles of neutrophils and/or macrophages in the inflammatory response and neo-intima formation in balloon-injured rat carotid arteries.

In the current study, we have extended our targeted cell delivery strategy to use of induced-pluripotent endothelial stem cells (iPS-ECs). We have prepared rat iPS (RiPS) cells by reprogramming fibroblasts isolated from rat embryos. The RiPS cells were oriented to differentiate into ECs and transduced with IL8RA/B and/or CCR2/5 for targeted cell therapy in rats with balloon-induced carotid injuries. We hypothesized that RiPS-ECs that overexpress IL8RA/RB, CCR2/5, or both receptor genes to differentiated cell therapy in rats with balloon-induced carotid injuries. In brief, 1 × 10⁶ RiPS cells in 100 μl of phosphate-buffered saline (PBS) were injected via a 21-G needle into the dorsal flanks of severe combined immunodeficiency (SCID) mice. Teratomas were recovered 4–5 weeks postinjection and processed for histological analysis.

Characterization of RiPS Cells. RiPS cell colonies were cultured and expanded in iPS culture medium (with mitomycin-inactivated rat embryonic fibroblast as feeder cells) for characterization. To evaluate the pluripotency of RiPS cells, cells were stained using the Vector Blue Alkaline Phosphatase Substrate Kit III (Vector Laboratories, Burlingame, CA, www.vectorlabs.com) according to the manufacturer’s instructions [16, 21]. RT-PCR analysis was used as an additional method to confirm that the iPS cells expressed undifferentiated embryonic stem cell-marker genes Oct4 [16, 21]. In vivo teratoma formation was assessed to confirm pluripotency of RiPS cells [16]. In brief, 1 × 10⁶ RiPS cells in 100 μl of phosphate-buffered saline (PBS) were injected via a 21-G needle into the dorsal flanks of severe combined immunodeficiency (SCID) mice. Teratomas were recovered 4–5 weeks postinjection and processed for histological analysis.

Characterization of Rat iPS-ECs Transduced with IL8RA/B, CCR2/5, or AdNull Adenoviral Vectors. Rat iPS-ECs overexpressing IL8RA/B, CCR2/5, or both receptors were generated using adenoviral vectors containing IL8RA, IL8RB, CCR2, or CCR5 and green fluorescent protein (GFP) genes using the AdEasy Adenoviral Vector System (Stratagene) as previously described [10, 12, 22, 23]. RiPS-ECs were grown to 80% confluence in EC growth medium (cat. no. MCD8-131, Vec Technologies, Rensselaer, NY). The iPS-ECs phenotype was confirmed by immunostaining with Abs against endothelial markers including endothelial nitric oxide synthase (eNOS), von Willebrand factor (vWF), and CD31 as described previously [12].

Characterization of Rat iPS-ECs Transduced with IL8RA/B, CCR2/5, or AdNull Adenoviral Vectors. Rat iPS-ECs overexpressing IL8RA/B, CCR2/5, or both receptors were generated using adenoviral vectors containing IL8RA, IL8RB, CCR2, or CCR5 and green fluorescent protein (GFP) genes using the AdEasy Adenoviral Vector System (Stratagene) as previously described [10, 12, 22, 23]. RiPS-ECs were grown to 80% confluence in EC growth medium (cat. no. MCD8-131, Vec Technologies, Rensselaer, NY) and treated with a mixture of adenoviruses containing IL8RA-GFP and IL8RB-GFP, CCR2-GFP and CCR5-GFP, or adenovirus containing only GFP (AdNull-GFP) as a control. Eighteen hours after adenoviral transduction, fresh media was added to the cells, and 48 hours after transduction fluorescence imaging of the transduced ECs exhibited green fluorescence, confirming GFP expression [10, 12, 22, 23].

To confirm the expression of IL8RA/B and CCR2/5 in transduced iPS-ECs, cells were fixed in 4% paraformaldehyde, permeabilized in 0.1% Triton X-100 in PBS, and stained with selective primary antibodies against IL8RA, IL8RB, CCR2, or CCR5 and counterstained with DAPI as a nuclear marker [10]. Stained ECs were mounted for fluorescent microscopic analysis with a computerized Leica DM6000 system [10].

In Vivo Studies

Animals and Procedures. Twelve-week-old male Sprague Dawley Rats (Charles River Laboratories) were maintained at a constant

Materials and Methods

Cell Lines and In Vitro Studies

Reprogramming of Rat Fibroblasts into RiPS Cells. Rat embryonic fibroblasts (from E14.5 embryos) were isolated following the protocol described previously with slight modification [16–20]. Isolated embryonic fibroblasts were de-differentiated into iPS cells by transduction with polycistronic lentiviral vectors containing the genes for the transcription factors Oct4, Sox2, and Klf4, as described previously [16, 21]. Cultured mitomycin-inactivated embryonic fibroblasts (passage 3) were used as feeder cells in the iPS culture medium. The iPS culture medium was DMEM containing the supplements: 1x l-glutamine, 1x penicillin/streptomycin, and 1x nonessential amino acids, 1x nucleosides, 15% FBS, 2-mercaptoethanol, and leukemia inhibitory factor. An additional combination of MEK inhibitor (0.5 μM PD0325901), GSK3 inhibitor (3 μM CHIR99021), and ALK5 inhibitor (0.5 μM A-83-01) were added to the culture medium.

www.StemCellsTM.com © 2017 The Authors Stem Cells Translational Medicine published by Wiley Periodicals, Inc. on behalf of AlphaMed Press
temperature (24 ± 1°C), humidity (60 ± 5%), and light cycle (6 a.m. to 6 p.m.) and fed standard rat pellet diet ad libitum [10, 12, 22, 23]. Protocols were approved by the Institutional Animal Care and Use Committee (IACUC) at the University of Alabama at Birmingham (UAB) and were consistent with the Guide for the Care and Use of Laboratory Animals published by the National Institutes of Health.

All rats were anesthetized with ketamine/xylazine (100/10 mg/kg BW) and subjected to implantation of a femoral venous catheter at 1 day before balloon injury of the right carotid artery (RCA). On the following day, rats were anesthetized with ketamine and xylazine and underwent balloon injury of the RCA as described previously [10, 12]. Briefly, a 2F Fogarty balloon catheter (Baxter V. Mueller) was introduced through the external carotid artery and advanced into the thoracic aorta. The balloon was inflated with saline to distend the common carotid artery and was pulled back to the external carotid artery. After six repetitions of this procedure, the catheter was removed, the external carotid artery was ligated and the wound was closed. The left carotid artery (LCA) was not damaged and served as a control. The LCA was used as an uninjured control. Immediately after RCA injury, rat were randomly divided into five treatment groups and received i.v. transfection of iPSC-ECs transduced with the empty adenoviral vector (RiPS-AdNull-iPS-EC, 1.5 × 10⁶ cells per rat); iPSC-ECs overexpressing IL8RA/B (RiPS-IL8RA/B-ECs, 1.5 × 10⁶ cells per rat), iPSC-ECs overexpressing CCR2/5 (RiPS-CCR2/5-ECs, 1.5 × 10⁶ cells per rat), iPSC-ECs overexpressing both receptors (RiPS-IL8RA/B+CCR2/5-ECs, 1.5 × 10⁶ cells per rat), or saline (Vehicle control) [10, 12, 22, 23].

Rats were sacrificed 1 or 14 days after RCA injury for histological (neutrophils and monocytes/macrophages infiltration) and biochemical (inflammatory cytokine expression) or neointima formation analyses, respectively.

Real-Time Quantitative RT-PCR Analysis for mRNA Quantitation of Inflammatory Mediators. Rats were sacrificed 24 hours postinjury and RNA was extracted from the RCA and LCA, reverse transcribed to cDNA and amplified by real-time quantitative PCR for the neutrophil attractant CINC-2b (equivalent to IL8 in human) and the macrophage attractant CCL2/MCP-1. The PCR primers for CINC-2b were: forward 5'-TGAAGGCGCTCTGTCACGCT-3' and reverse 3'-TGACTTCCTGTCGGTG-5'; and for CCL2/MCP-1 were: forward 5'-ATGAGGCGCTCAGCCTACG-3' and reverse 3'-GGTGCTGAAGTCCCTAGGGT-5' [10, 12]. Levels of specific mRNA were normalized using 18S RNA, forward 5'-GAAACGCTACCACATCC-3' and reverse 3'-GAAACGCTACCACATCC-5'. Levels of specific mRNAs were normalized using 18S RNA, forward 5'-GAAACGCTACCACATCC-3' and reverse 3'-GAAACGCTACCACATCC-5'.

Measurement of Inflammatory Mediator Protein Levels. Protein levels of inflammatory cytokines were measured from protein homogenates of the injured RCA and uninjured LCA at 24 hours postinjury using a multiplex rat-specific magnetic beads-based sandwich immunoassay kit (Milliplex Rat Cytokine/Chemokine Panel, Millipore, Billerica, MA) with the Luminex xMap analyzer as described previously [1170].

Immunohistochemical Assessment of Infiltration of Neutrophils and Monocytes/Macrophages into Injured Carotid Arteries. The avidin-biotin-peroxidase immunohistochemical technique was used to detect neutrophils (myeloperoxidase, MPO+) and monocytes/macrophages (ED1+) in paraffin-embedded sections using specific primary antibodies and a VECTASTAIN ABC Kit (Vector Laboratories, Burlingame, CA) as described previously [10, 12, 22].

Morphometric Analysis of Neointima Formation. Neointimal and medial areas were determined using 5 μm cross-sections of the injured RCA and uninjured LCA at 14 days postinjury, as described previously [10, 12]. The computer-based NIH ImageJ Morphometric system was used for morphometric analysis. Multiple H/E-stained cross-sections from the middle third of each vessel were used for quantitation, and the measurements were averaged for statistical analysis. The cross-sectional areas of the vessel within the external elastic lamina (EEL area), within the internal elastic lamina (IEL area), and within the lumen (lumen area) were measured. Neointima formation in the injured RCA was determined by calculating the neointima-to-media area ratio [10, 12].

Statistical Analysis

Age matched rats were used throughout. All statistical analyses were done using SigmaStat statistical package (Version 3.5). A Student t test was used for comparisons between individual groups and one-way ANOVA was used for comparisons across multiple groups. When the F test ANOVA was statistically significant, a Tukey test was applied for further analysis [10, 12]. Results are presented as means ± SEM. All statistically significant differences are reported when p < .05.

RESULTS

RiPS-ECs Express EC Markers

RiPS cells generated from rat embryonic fibroblasts expressed alkaline phosphatase, a stem cell marker (Fig. 1A). Oct4 mRNA expression was detected in RiPS cells (Fig. 1B). When these iPSC cells were injected into the dorsal flanks of SCID mice, teratomas containing tissue derived from all three germ layers was obtained (Fig. 1C–1E). These results demonstrate that the rat embryonic fibroblasts have been effectively reprogrammed to iPSC cells. Differentiated RiPS-ECs showed a monolayer cobblestone EC phenotype and expressed the EC markers eNOS, vWF, and CD31 (Fig. 1F–1I). Oct4 mRNA was not detected in differentiated iPSC-ECs (data not shown).

Adenoviral Transduced RiPS-ECs Overexpress IL8RA/RB and CCR2/5 Receptors

Transduction with adenoviral vectors carrying IL8RA, IL8RB, CCR2, and/or CCR2/5 genes caused overexpression of these receptors in RiPS-ECs 72 hours after transduction (Fig. 2A, 2B). The adenoviral transduction did not alter the expression of eNOS or CD31 in RiPS-ECs (Fig. 2A, 2B).

Transfusion of RiPS-ECs Overexpressing IL8RA/RB and/or CCR2/5 Decreases Expression of Neutrophil and Macrophage Chemoattractants in Injured RCA

Balloon injury significantly increased mRNA expression of the neutrophil chemoattractant CINC-2β (the rat homolog of IL8) and the macrophage chemoattractant CCL2/MCP-1 in RCA at 24 hours postinjury. Transfusion of RiPS-ECs overexpressing IL8RA/RB (RiPS-IL8RA/RB-ECs), CCR2/5 (RiPS-CCR2/5-ECs), or both (RiPS-IL8RA/RB+CCR2/5-ECs) significantly decreased (>65%) the injury-induced CINC-2β and CCL2/
MCP-1 mRNA expression in RCA. Transfusion of RiPS-AdNull-ECs did not alter mRNA levels of Cinc-2β or CCL2/MCP-1 in RCA (Fig. 3).

Similarly, balloon injury caused increases in the protein levels of the inflammatory cytokines CCL2/MCP-1, vascular endothelial growth factor, interleukin (IL)—1b, and CCL5/regulated on activation, normal T cell expressed and secreted (RANTES) in the injured RCA, compared to the uninjured LCA, at 24 hours postinjury. Levels of these inflammatory cytokines were reduced in injured RCA of rats transfused with RiPS-IL8RA/B-ECs, RiPS-CCR2/5-ECs, or

Figure 1. Rat-induced pluripotent stem (RiPS) cells were generated from rat embryonic fibroblasts and then differentiated to endothelial cells (RiPS-ECs). (A): RiPS Cells were stained with alkaline phosphatase (a stem cell marker); (B) reverse transcription-PCR products of transduced transcriptional factor OCT4 (144 base pair [bp]) and 18S (168 bp, as a PCR control) in RiPS cells; (C–E) teratoma containing tissue derived from all three germ layers was obtained when RiPS cells were injected into the dorsal flanks of severe combined immunodeficiency mice. Photo micrograph: magnification ×100 (Scale bars = 100 μm). (C): Glandular epithelium endoderm derived from endoderm; (D) cartilage derived from mesoderm; (E) nerve tissue derived from ectoderm; (F–I) RiPS-differentiated ECs exhibited typical cobblestone morphology (F) and expressed eNOS (G), vWF (H), and CD31 (I). Photo micrograph: magnification x200 (F), magnification x400 (G–I). Abbreviations: OCT4, a transcriptional factor; 18S, a ribosomal RNA; Cinc-2β, chemokine CINC-2β; eNOS, endothelial nitric oxide synthase; RiPS, induced pluripotent stem; vWF, von Willebrand factor.

MCP-1 mRNA expression in RCA. Transfusion of RiPS-AdNull-ECs did not alter mRNA levels of Cinc-2β or CCL2/MCP-1 in RCA (Fig. 3).

Figure 2. Characterization of RiPS-ECs transduced with IL8RA/B, CCR2/5, or AdNull adenoviral vectors. (A): Fluorescence micrographs showing expression of endothelial cell (EC) markers endothelial nitric oxide synthase (eNOS) and CD31, and very low level of expression of IL8RA/B and CCR2/5 in RiPS-ECs transduced with empty adenovirus carrying only green fluorescent protein gene. (B): Fluorescence micrographs showing overexpression of IL8RA/B and CCR2/5 in iPS-ECs transduced with Ad-CXCR1/2 and Ad-CCR2/5. The adenoviral transduction did not alter the expression of eNOS or CD31 in these cells. Photo micrograph: magnification ×400. Abbreviations: CCR, C-C chemokine receptors; IL, interleukin; RiPS, rat-induced pluripotent stem cells.
RiPS-IL8RA/B-CCR2/5-ECs, as well as in RCA of rats transfused with RiPS-AdNull-ECs (Fig. 4).

**RiPS-ECs Overexpressing IL8RA/RB or CCR2/5 Decrease Migration of Neutrophils and Monocytes/Macrophages into Injured RCA**

Balloon injury significantly stimulated infiltration of neutrophils and monocytes/macrophages into adventitia of injured RCA at 24 hours postinjury. Transfusion of RiPS-IL8RA/B-ECs, RiPS-CCR2/5-ECs, or RiPS-IL8RA/B-CCR2/5-ECs significantly decreased (>65%) the injury-induced neutrophil and monocyte/macrophage infiltration, but transfusion with RiPS-AdNull-ECs did not alter inflammatory leukocyte infiltration into RCA (Figs. 5 and 6).

**Transfusion of RiPS-RA/RA-ECs, RiPS-CCR2/5-ECs, or RiPS-RA/RB-CCR2/5-ECs Inhibits Neointima Formation in Injured RCA**

Balloon injury-induced neointima formation in RCA was inhibited by transfusion with RiPS-IL8RA/RA-ECs, RiPS-CCR2/5-ECs, or RiPS-IL8RA/RA-CCR2/5-ECs, but not control RiPS-AdNull-ECs. RiPS-IL8RA/RA-ECs and RiPS-CCR2/5-ECs were equally effective in preventing neointima formation. The combination of IL8RA/RB and CCR2/5 overexpression in RiPS-ECs had a slight, statistically nonsignificant, additive inhibitory effect on neointima formation in RCA (Fig. 7).

**DISCUSSION**

This study demonstrated that targeted cell therapy using ECs derived from RiPS cells overexpressing IL8RA/RB and/or CCR2/5 attenuates inflammation and neointima formation after balloon injury of the carotid artery. We were able to successfully generate rat iPSCs from rat embryonic fibroblasts and orient them into ECs. Intravenous infusion of RiPS-ECs overexpressing IL8RA/RB and/or CCR2/5 outcompeted inhibited neutrophils and macrophages in the injured carotid artery, decreased inflammatory cytokine expression at 24-hour postinjury, and reduced neointima formation at 2 weeks postinjury. Thus, we have shown that inhibiting neutrophil and/or macrophage infiltration during the early inflammatory response to endoluminal vascular injury decreases subsequent adverse vascular remodeling.

Use of iPSCs can eventually enable the development of autologous cell therapy and thus overcome the major hurdle that stands in the way of practical application of cell therapy for human diseases. The successful use of rat iPSCs derived into ECs in preventing the inflammation and adverse vascular remodeling that results from acute vascular injury provides proof of concept in support of potential therapeutic interventions using autologous cell therapy, as described by Volz et al. [24]. A major concern of using cell therapy as a potential treatment for human diseases is rejection of the transplanted cells; autologous cell therapy overcomes the obstacle of rejection [24].

We have previously demonstrated that targeted cell therapy with RAECs and human iPSCs overexpressing IL8RA/RB inhibits early inflammatory mediator expression, inflammatory cell infiltration, and subsequent neointima formation in a variety of models of acute vascular injury, including balloon-injured rat carotid arteries [10, 12], monocrotalin-induced acute lung injury [22], and coronary ligation-induced myocardial infarction [23]. In the current study, RiPS-ECs overexpressing IL8RA/RB achieved similar protective effects against inflammatory responses and neointima formation, indicating consistency of targeting neutrophil chemotaxis. Our previous work has also shown that inhibiting both IL8RA and RB concurrently is more effective at reducing neointima formation than inhibiting either receptor alone [10]. Further, we have shown that our targeted cell therapy is EC specific, since smooth muscle cells overexpressing IL8RA/RB did not inhibit neointima formation in the rat carotid injury model [10]. In the current study, there were decreases in inflammatory cytokine expression and a trend toward decreases in neutrophil and monocyte/macrophage infiltration in injured arteries of RiPS-AdNull-ECs transfused animals. We postulate that these anti-inflammatory effects...
may be related to low levels of IL8RA/B and CCR2/5 expression in RiPS-AdNull-ECs. However, the attenuation of the early inflammatory response in the injured RCA of rats treated with RiPS-Null-ECs was not reflected in a reduction in neointima formation, consistent with our previous findings in balloon-injured carotid arteries of rats treated with human iPS-AdNull-ECs versus human iPS-IL8RA/B-ECs [12]. As we previously demonstrated, both decreasing proinflammatory responses and accelerating reendothelialization contribute to inhibition of neointima formation in balloon-injured rat carotid arteries, and transfusion of IL8 receptor-targeted ECs is more effective than transfusion of equal numbers of untargeted ECs in inhibiting the later phases of the inflammatory response, for example, cell migration, proliferation, remodeling of matrix proteins, and neointima formation, as shown in our previous studies [12].

A novel aspect of the current study is the demonstration that RiPS-ECs overexpressing CCR2/5 protect the vasculature against endoluminal injury. The chemokine receptor CCR2 is expressed abundantly on the "inflammatory" subset of blood monocytes [25], as well as other immune/inflammatory cell types such as dendritic cells and memory Th1 cells [26, 27]. CCR2 is a G protein-coupled receptor that binds multiple ligands, characterized as macrophage chemoattractant proteins, including CCL2/MCP-1, CCL8/MCP-2, CCL7/MCP-3, and CCL13/MCP-4. Of these ligands, MCP-1 is the best studied, and CCR2 is considered to be its major receptor [13, 28, 29]. The CCR2/MCP-1 axis mediates emigration of inflammatory monocytes from bone marrow to blood and immigration of blood monocytes from blood to inflamed tissues [14, 30–36].

CCR5 is expressed predominantly on macrophages that have been differentiated from blood monocytes and Th1 cells that have been activated in response to inflammatory stimuli [13, 37], and is also expressed on nonimmune cells such as osteoclasts [38] and VSMCs [39]. CCR5 is a G protein-coupled receptor that binds multiple ligands, including CCL4/macroage inflammatory protein-1β (MIP-1β), CCL5/RANTES, CCL3/MIP-1α, CCL8/MCP-2, and CCL3-like 1 (CCL3L1)/LD78. CCR5 contributes to the survival of macrophages during inflammation and infection [40] and may function to retain tissue macrophages in inflamed tissue [41]. Consistent with their key role in monocyte trafficking and macrophage survival/retention, CCR2/5 have been shown to drive inflammation in a number of animal models of vascular disease, including atherosclerosis [42–51], and restenosis [52–61] following revascularization. Genetic ablation [52, 59] or pharmacologic inhibition of CCR2/5 [54–57, 61] has been shown to reduce macrophage infiltration and neointima formation following vascular injury. However, systemic deletion of CCR2/5 gene expression [54–57, 61] has been shown to reduce macrophage infiltration and neointima formation following vascular injury. However, systemic deletion of CCR2/5 gene expression [62–66] in mice and blocking of CCR5 with a pharmacologic antagonist in humans

Figure 4. Effects of RiPS-AdNull-ECs, RiPS-IL8RA/B-ECs, and/or RiPS-CCR2/5-ECs transfusion on protein levels of chemokines and cytokines in injured right carotid artery at 24 hours postinjury and cell transfusion. Cytokine/chemokine levels were measured in whole vessel homogenates using commercially available Multiplexed rat specific magnetic beads-based sandwich immunoassay kits with a Luminex xMAP analyzer (Milliplex Rat Cytokine/Chemokine Panel, Millipore). Results are means ± SEM, (n) = number of vessels. # p < .05, compared to Uninjured control group; * p < .05, compared to Injured control group. (A) CCL2/MCP-1, (B) vascular endothelial growth factor, (C) IL-1β (interleukin 1-β), and (D) CCL5/ RANTES (regulated on activation, normal T cell expressed and secreted). Abbreviations: CCL, C-C chemokine ligand; CCR, C-C chemokine receptors; EC, endothelial cell; IL, interleukin; MCP, monocyte chemoattractant protein; RANTES, regulated on activation, normal T cell expressed and secreted; RiPS, rat-induced pluripotent stem cells; VEGF, vascular endothelial growth factor.
[67] have been linked to hepatotoxicity. Accordingly, this approach likely has little translational potential for treatment of CVD. Our strategy utilizing dual targeting of CCR2 and CCR5 by RiPS-CCR2/5-ECs appears to be a more efficacious and safer approach with greater potential for translation to treatment of patient with CVD.

Interestingly, inhibiting both neutrophils and macrophages with RiPS-IL8RA/B-CCR2/5-ECs, did not have a cumulative effect on injury-induced vascular inflammatory responses or neointima formation. Further research is needed to delineate the detailed cellular/molecular mechanisms and signaling pathways by which these leukocyte subtypes mediate the vascular injury response.

Figure 5. Effects of RiPS-AdNull-ECs, RiPS-IL8RA/B-ECs, and/or RiPS-CCR2/5-ECs transfusion on neutrophils infiltration into injured RCA at 24 hours postinjury and cell transfusion. Top: Representative photo micrographs of neutrophil (MPO+) infiltration into adventitia of rat arteries. Photo micrograph: magnification x630. Bottom: Numbers of MPO+ cells were counted in 6 fields of cross-sections of each vessel. Results are means ± SEM, (n) = number of vessels. # p < .05, compared to Uninjured control group; * p < .05, compared to Injured control group. Abbreviations: CCR, C-C chemokine receptors; EC, endothelial cell; MPO, myeloperoxidase; IL, interleukin; RiPS, rat-induced pluripotent stem cells.

Figure 6. Effects of RiPS-AdNull-ECs, RiPS-IL8RA/B-ECs, and/or RiPS-CCR2/5-ECs transfusion on monocytes/macrophages infiltration into injured RCA at 24 hours postinjury and cell transfusion. Top: Representative micrographs of monocytes/macrophages (ED1+) infiltration into adventitia of rat arteries. Photo micrograph: magnification x630. Bottom: Numbers of ED1+ cells were counted in 6 fields of cross-sections of each vessel. Results are means ± SEM, (n) = number of vessels. # p < .05, compared to Uninjured control group; * p < .05, compared to Injured control group. Abbreviations: CCR, C-C chemokine receptors; EC, endothelial cell; IL, interleukin; RiPS, rat-induced pluripotent stem cells.
However, our data clearly indicate that targeting delivery of RiPS-ECs overexpressing either IL8RA/B or CCR2/5 is an effective treatment for acute vascular injury.

**CONCLUSION**

Transfused RiPS-ECs overexpressing IL8RA/B and/or CCR2/5 migrate into injured vessels and compete with neutrophil/macrophage
infiltration, preventing inflammatory responses and neointima formation. Targeted delivery of iPSC-ECs with a homing device to inflammatory mediators in injured arteries provides a novel strategy for the treatment of CVDS.

ACKNOWLEDGMENT

This study was supported by National Institutes of Health (NIH) grants: RO1 HL116727 (Y.-F. Chen), RO1 HL087980 (S. Oparil), R56 HL128285-01A1 (D. Xing), and T32 HL07457 (S. Oparil, S. Giordano); an American Heart Association (AHA) grant SDG 0930098N (F. G. Hage); a Veterans Affairs Biomedical Laboratory Research & Development ServiceMerit Award OMB 4040-0001 (F. G. Hage); and a CCVC William W. Featheringill Innovative Award of the University of Alabama at Birmingham (Y.-F. Chen).

DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST

The authors indicate no potential conflicts of interest.

REFERENCES

1. Xing D, Miller A, Novak L et al. Estradiol and progestins differentially modulate leukocyte infiltration after vascular injury. Circulation 2004;109:234–241.

2. Xing D, Feng W, Miller AP et al. Estrogen modulates TNF-alpha-induced inflammatory responses in rat aortic smooth muscle cells through estrogen receptor-beta activation. Am J Physiol Heart Circ Physiol 2007;292:H2607–H2612.

3. Xing D, Nozell S, Chen YF et al. Estrogen and mechanisms of vascular protection. Arteioscler Thromb Vasc Biol 2009;29:289–295.

4. Miller AP, Feng W, Xing D et al. Estrogen modulates inflammatory mediator expression and neutrophil chemotaxis in injured arteries. Circulation 2004;110:1664–1669.

5. Li G, Chen YF, Greene GL et al. Estrogen inhibits vascular smooth muscle cell-dependent adventitial fibroblast migration in vitro. Circulation 1999;100:1639–1645.

6. Li G, Chen SJ, Opari S et al. Direct in vivo evidence demonstrating neointimal suppression of adventitial fibroblasts after balloon injury of rat carotid arteries. Circulation 2000;101:1362–1365.

7. Li G, Chen YF, Kelpse SS et al. Estrogen attenuates integrin-beta(3)-dependent adventitial fibroblast migration after inhibition of osteopontin production in vascular smooth muscle cells. Circulation 2000;101:2949–2955.

8. Miller A, Xing D, Feng W et al. Aged rats lose vasoprotective and anti-inflammatory actions of estrogen in injured arteries. Menopause 2007;14:251–260.

9. Xing D, Feng W, Nöt L et al. Increased protein O-GlcNAc modification inhibits inflammatory and neointimal responses to acute endoluminal arterial injury. Am J Physiol Heart Circ Physiol 2008;295:H335–H342.

10. Xing D, Li P, Gong K et al. Endothelial cells overexpressing interleukin-8 receptors reduce inflammatory and neointimal responses to arterial injury. Circulation 2012;125:1533–1541.

11. Li G, Opari S, Kelpse SS et al. Fibroblast growth factor receptor-1 signaling induces osteopontin expression and vascular smooth muscle cell-dependent adventitial fibroblast migration in vitro. Circulation 2002;106:854–859.

12. Giordano S, Zhao X, Xing D et al. Targeted delivery of human iPSC-ECs overexpressing IL-8 receptors inhibits neointimal and inflammatory responses to vascular injury in the rat. Am J Physiol Heart Circ Physiol 2016;310:H705–H715.

13. Zhao Q. Dual targeting of CCR2 and CCR5: Therapeutic potential for immunologic and cardiovascular diseases. J Leukoc Biol 2010;88:41–55.

14. Mack M, Chak J, Simonis C et al. Expression and characterization of the chemokine receptors CCR2 and CCR5 in mice. J Immunol 2001;166:4697–4704.

15. Xing D, Gong K, Feng W et al. O-GlcNAc modification of NF-kB p65 inhibits TNF-alpha-induced inflammatory mediator expression in rat aortic smooth muscle cells. PLoS One 2011;6:e24021.

16. Chang CW, Lai YS, Pawlik KM et al. Polyclonal lentinan vector for “hit and run” reprogramming of adult skin fibroblasts to induced pluri-potent stem cells. SCIENCE 2009;27:1042–1049.

17. Chang MY, Kim D, Kim CH et al. Direct reprogramming of rat neural precursor cells and fibroblasts into pluripotent stem cells. PLoS One 2010;5:e9838.

18. Lisiovsky M, Chuykin I, Ranjan A et al. Derivation, characterization, and stable transfection of induced pluri-potent stem cells from Fischer344 rats. PLoS One 2011;6:e27345.

19. Lisiovsky MA, Chui kin IA, Ranjan A et al. [Genetic manipulation and studying of differentiation properties of rat induced pluri-potent stem cells]. Tsiologl 2011;53:946–951.

20. Rajara jan K, Engels MC, Wu SM. Reprogramming of mouse, rat, pig, and human fibroblasts into iPSC cells. Curr Protoc Mol Biol 2012;Chapter 23:Unit 23.15.

21. Zang Z, Jones A, Sun CW et al. PRC2 complexes with JARID2, MTF2, and esPRCP248 in ES cells to modulate ES cell pluripotency and somatic cell reprogramming. SCIENCE 2011;29:229–240.

22. Fu J, Chen YF, Zhao X et al. Targeted delivery of pulmonary arterial endothelial cells overexpressing interleukin-8 receptors attenuates monocrotaline-induced pulmonary vascular remodeling. Arteioscler Thromb Vasc Biol 2014;34:1539–1547.

23. Zhao X, Zhang W, Xing D et al. Endothelial cells overexpressing IL-8 receptor reduce cardiac remodeling and dysfunction following myocardial infarction. Am J Physiol Heart Circ Physiol 2013;305:H590–H598.

24. Volf KS, Miljan E, Kho e a et al. Development of pluripotent stem cells for vascular therapy. Vascul Pharmacol 2012;56:288–296.

25. Geissmann F, Jung S, Littman DR. Blood monocytes consist of two principal subsets with distinct migratory properties. Immunity 2003;19:71–82.

26. Sozzani S, Luini W, Borsatti A et al. Receptor expression and responsiveness of human dendritic cells to a defined set of CC and CXC chemokines. J Immunol 1997;159:1993–2000.

27. Loetscher P, Seitz M, Baggiolini M et al. Interleukin-2 regulates CC chemokine receptor expression and chemotactic responsiveness in T lymphocytes. J Exp Med 1996;184:569–577.

28. Gerard C, Rolls BJ. Chemokines and cardiovascular disease. Nat Immunol 2001;2:108–115.

29. Charo IF, Ransohoff RM. The many roles of chemokines and chemokine receptors in inflammation. N Engl J Med 2006;354:610–621.

30. Boring L, Gosling J, Chensue SW et al. Impaired monocyte migration and reduced type 1 (Th1) cytokine responses in C-C chemokine receptor 2 knockout mice. J Clin Invest 1997;100:2552–2561.

31. Kuziel WA, Morgan SJ, Dawson TC et al. Severe reduction in leucocyte adhesion and monocyte extravasation in mice deficient in CC chemokine receptor 2. Proc Natl Acad Sci U S A 1997;94:12053–12058.

32. Kurihara T, Warr G, Loy J et al. Defects in macrophage recruitment and host defense in mice lacking the CCR2 chemokine receptor. J Exp Med 1997;186:1757–1762.

33. Lu B, Rutledge BJ, Gu L et al. Abnormalities in monocyte recruitment and cytokine expression in monocyte chemoattractant protein-1-deficient mice. J Exp Med 1998;187:601–608.

34. Brodmerkel CM, Huber R, Covington M et al. Discovery and pharmacological characterization of a novel rodent-active CCR2 antagonist, INCB3344. J Immunol 2005;175:5370–5378.
Serbina NV, Pamer EG. Monocyte migration from bone marrow during bacterial infection requires signals mediated by chemokine receptor CCR2. Nat Immunol 2006;7:311–317.

Serbina NV, Salazar-Mather TP, Biron CA et al. TNF/INOS-producing dendritic cells mediate innate immune defense against bacterial infection. Immunity 2003;19:59–70.

Wu L, Paxton WA, Kassam N et al. CCR5 levels and expression pattern correlate with infectability by macrophage-tropic HIV-1, in vitro. J Exp Med 1997;185:1681–1691.

Oba Y, Lee JW, Ehrlich LA et al. MIP-1alpha utilizes both CCR1 and CCR5 to induce osteoclast formation and increase adhesion of myeloma cells to marrow stromal cells. Exp Hematol 2005;33:272–278.

Schecter AD, Calderon TM, Berman AB et al. Human vascular smooth muscle cells possess functional CCR5. J Biol Chem 2000;275:5466–5471.

Tyner JW, Uchida O, Kajiwara N et al. CCL5-CC chemokine receptor 5 interaction provides antiapoptotic signals for macrophage survival during viral infection. Nat Med 2005;11:1180–1187.

Katschke KJ, Rotzmann JB, Ruth JH et al. Differential expression of chemokine receptors on peripheral blood, synovial fluid, and synovial tissue monocytes/macrophages in rheumatoid arthritis. Arthritis Rheum 2001;44:1022–1032.

Boring L, Gosling J, Cleary M et al. Decreased lesion formation in CCR2-/− mice reveals a role for chemokines in the initiation of atherosclerosis. Nature 1998;394:894–897.

Dawson TC, Kuziel WA, Osahar TA et al. Absence of CC chemokine receptor-2 reduces atherosclerosis in apolipoprotein E-deficient mice. Atherosclerosis 1999;143:205–211.

Braunersreuther V, Zernecke A, Arnaud C et al. Ccr5 but not Ccr1 deficiency reduces development of diet-induced atherosclerosis in mice. Arterioscler Thromb Vasc Biol 2007;27:373–379.

Quinones MP, Martinez HG, Jimenez F et al. Essential role of monocyte chemoattractant protein-1 gene therapy attenuates atherosclerosis in hypercholesterolemic rabbits. Circulation 2002;105:2905–2910.

Ohtani K, Usui M, Nakano K et al. Anti-monocyte chemotractant protein-1 gene therapy reduces experimental in-stent restenosis in hypercholesterolemic rabbits and monkeys. Gene Ther 2004;11:1273–1282.

Zernecke A, Liehn EA, Gao JL et al. Deficiency in CCR5 but not CCR1 protects against neointima formation in atherosclerosis-prone mice: Involvement of IL-10. Blood 2006;107:4240–4243.

Krohn R, Raffetseder U, Bot I et al. Y-box binding protein-1 controls CC chemokine ligand-5 (CCL5) expression in smooth muscle cells and contributes to neointima formation in atherosclerosis-prone mice. Circulation 2007;116:1812–1820.

Schober A, Manka D, von Hundeshagen P et al. Deposition of platelet RANTES triggering monocyte recruitment requires P-selectin and is involved in neointima formation after arterial injury. Circulation 2002;106:1523–1529.

Dambach DM, Watson LM, Gray KR et al. Role of CCR2 in macrophage migration into the liver during acetaminophen-induced hepatotoxicity in the mouse. Hepatology 2002;35:1103–1113.

Ajuebor MN, Hogaboam CM, Le T et al. C-C chemokine ligand 2/monocyte chemotractant protein-1 directly inhibits NK cell IL-4 production and is hepatoprotective in T cell-mediated hepatitis in the mouse. J Immunol 2003;170:5252–5259.

Ajuebor MN, Aspinall AJ, Zhou F et al. Lack of chemokine receptor CCR5 promotes murine fulminant liver failure by preventing the apoptosis of activated CD14-restricted NKT cells. J Immunol 2005;174:8027–8037.

Ajuebor MN, Carey JA, Swain MG. CCR5 in T cell-mediated liver diseases: What’s going on? J Immunol 2006;177:2039–2045.

Ajuebor MN, Wondimu Z, Hogaboam CM et al. CCR5 deficiency drives enhanced natural killer cell trafficking to and activation within the liver in murine T cell-mediated hepatitis. Am J Pathol 2007;170:1975–1988.

Emmell JMP, Rockstroh JK. CCR5 antagonists: Comparison of efficacy, side effects, pharmacokinetics and interactions—Review of the literature. Eur J Med Res. 2007;12:409–417.